Exosome technology: Downsizing Cell Therapy to Nano-Scale

Cell-free therapy based on exosomes is witnessing a surge of published scientific papers, a rise of IP and registered clinicals trials, all driven by a swelling avidity among investors to support this transformative nanomedicine approach. For cell-free treatment to become a reality, they need to overcome the many manufacturing hurdles posed by the large-scale production of purified exosomes. Cells for Cells, a clinical-stage biotech company, has announced the publication of new data of its OxiumTMEXO cell culture media for increased exosome production in Frontiers in Biotechnology and Bioengineering, a specialized journal of the field. The company is part of REGENERO, the Chilean consortium for regenerative medicine supported by state funding (CORFO). In a head-to-head comparison, OxiumTMEXO outmatched the standard DMEM (starvation protocol) and a commercially available medium for exosome production. OxiumTMEXO allowed different type of cells, including the broadly used mesenchymal stem cells, to increase by 3-folds their particle production. The isolated exosomes expressed the typical pan markers while preserving their functionality both in vitro and in vivo.